Formalin-inactivated Venezuelan equine encephalomyelitis vaccine was prepared from virus propagated in rolling-bottle cultures of chicken embryo cells. The attenuated, TC-83 strain of virus was propagated in these cultures with a maintenance medium consisting of serum-free medium 199 containing 0.25% human serum albumin and antibiotics. By adjustment of maintenance medium volume (100 to 300 ml) and multiplicity of inoculum (0.04 to 0.00004), high-titered yields of virus were obtained with minimal cell destruction at convenient harvest times, viz, 18 to 24 h postinoculation. Inactivation of virus at 37 C was complete between 8 to 10 h with 0.05% Formalin and within 6 to 8 h with 0.1% Formalin. Antigen extinction potency tests in mice indicated that potent vaccines could be produced at both Formalin concentrations and, furthermore, that potency was not adversely affected by inactivation periods of up to 96 h.
In an earlier paper, we outlined the usefulness of an inactivated Venezuelan equine encephalomyelitis (VEE) vaccine and described the preparation of such a vaccine from the Trinidad strain of VEE virus (3) . However, in view of the reluctance to use a product prepared from a highly virulent, "exotic" strain of VEE virus, studies were initiated to determine if an equally potent vaccine could be prepared from the now widely used attenuated TC-83 strain of VEE virus (8, 12) .
Reported here are results of studies on the parameters of production of a Formalin-inactivated VEE vaccine prepared from the attenuated, TC-83 strain of VEE virus grown in rolling-bottle cultures of chicken embryo cells (CEC).
MATERIALS AND METHODS
Viruses. The attenuated, TC-83 strain of VEE virus (8) Effect of Formalin concentration and length of inactivation period on vaccine potency. Because extended contact with Formalin or exposure to temperature above 0 C may result in destruction of virus antigens, 30 small lots of experimental vaccine were prepared from 18-to-24-h harvest fluids by using either 0.05 or 0.1% Formalin and inactivation periods of 24 to 96 h. Summarized in Table 4 are the results of single-dose potency assays performed on these vaccine lots. These data indicate that killed TC-83 strain is stable antigenically, even after inactivation for periods as long as 96 h. The volume of MM and preinactivation titers of the fluids used to prepare these vaccine lots varied from 100 to 300 ml and 10" to 1010.8 suckling mouse i.c. LD5, per ml, respectively. There was no correlation between these values and the potency test results.
Tests on selected lots of vaccine indicated that the methods employed resulted in a product that would meet current U.S. standards for safety and sterility (6) .
DISCUSSION
In this study we have employed the previously developed rolling-bottle technique (1) to propagate the attenuated, TC-83 strain of VEE virus. We showed that use of 200 or 300 ml of MM resulted in decreased cell destruction without a concomitant decrease in titer when harvests were made 12 to 24 h postinoculation. Furthermore, clarification by centrifugation and filtration also was used to remove additional cellular material. Studies on the effect of using various MOIs demonstrate that high dilutions of seed virus (i.e., low virus input) may be used without affecting the optimal time to harvest or the virus yield. Indeed, high-titered virus material with decreased amounts of cellular debris can be obtained in this system at several MOIs and at harvest times of 12 to 24 h by manipulating virus input and MM volume. For large-scale production, this latitude would be advantageous, because several factors could be adjusted to permit flexible production schedules.
Studies on Formalin inactivation at 37 C showed that TC-83 strain VEE virus was similar to the virulent Trinidad strain in terms of heat stability and sensitivity to Formalin (3). Because the standards for biological products of the Code of Federal Regulations require Formalin treatment at 37 C for a period three times that required to reduce virus to a nondetectable level, this would indicate a total inactivation period of between 24 and 30 h for vaccines made with 0.05% Formalin and a period of between 18 and 24 h when 0.1% Formalin is employed (6) . Data on 30 lots of vaccine prepared with both 0.05 and 0.1% Formalin and inactivated at 37 C for 24 to 96 h indicate that the potency of this vaccine is not adversely affected by prolonged contact with Formalin. Thus, for additional safety, the U.S. standards may easily be exceeded in terms of inactivation period without endangering the quality of the final product. Similar results were obtained with the Trinidad strain (3).
Because no correlation could be made between preinactivation titers and vaccine potencies, one must assume that even the harvests with the lowest titer (i.e., 10" suckling mouse i.c. LD50 per ml) contained sufficient antigenic mass for the production of a potent product. As was true for the Trinidad strain vaccine (3), high virus titers were consistently obtained in cultures maintained with 300 ml of MM, and thus large volumes of high-titered virus could easily be obtained by this method for large-scale production of vaccine.
In our earlier paper (3) we reviewed the problem of incomplete inactivation that plagued the earliest attempts to produce a Formalin-killed VEE vaccine. The usefulness and limitations of the live, attenuated TC-83 vaccine, which was developed to replace the old killed product, were also discussed (3). There are additional situations in which use of the live, attenuated product is inadvisable. For example, in countries where the disease is not present, but may be a threat, use of the live vaccine could result in the development of an enzootic focus of the vaccine virus in a rodentmosquito-rodent cycle. The isolation of the vaccine virus from mosquitoes in Louisiana by Pedersen et Use of a killed product would present none of the problems associated with live vaccine. Moreover, because the danger resulting from residual live virus is greatly minimized through the use of the attenuated, TC-83 strain virus, the vaccine described in this paper represents an improvement in safety as compared with the killed Trinidad strain product (3) . Use of such attenuated strains for killed products has been advocated for several years by Darwish and Hammon (4, 5) .
As with the killed Trinidad product (3), this vaccine will soon be tested in Equidae to establish dosage and persistence of immunity. Moreover, upon approval of the appropriate U.S. government regulating agencies, vaccine now being commercially produced by our method will be tested in volunteers to establish parameters for optimal dose and schedule of administration, as well as for persistence of immune response.
The killed product described here obviously cannot replace live, attenuated VEE vaccine under conditions where a rapid abatement of raging epizootics or epidemics of the disease must be affected. However, the killed product can be extremely useful in those situations where the live product is contraindicated.
